Overall mortality | Disease-specific mortality | ||||||
---|---|---|---|---|---|---|---|
Variable | n | HR | 95 % CI | p | HR | 95 % CI | p |
Age ≤ 50 years | 51 | 1 | 0.92 | 1 | 0.45 | ||
Age > 50 years | 92 | 0.96 | 0.44–2.08 | 1.49 | 0.54–4.12 | ||
Postmenopausal | 85 | 1.06 | 0.50–2.27 | 0.87 | 0.94 | 0.38–2.34 | 0.89 |
Clinical stage | <0 .0001 | <0.0001 | |||||
stages I & II | 101 | 1 | 1 | ||||
Stage III | 31 | 3.00 | 1.24–7.24 | 1.92 | 0.58–6.39 | ||
Stage IV | 11 | 10.89 | 4.35–27.23 | 14.02 | 5.05–38.94 | ||
Histology | 0.14 | 0.92 | |||||
IDC | 130 | 1 | 1 | ||||
ILC | 8 | 2.94 | 1.02–8.51 | 1.06 | 0.14–7.99 | ||
Other subtypes | 5 | 1.07 | 0.14–7.95 | 1.51 | 0.20–11.35 | ||
IDC tumor grade | 0.80 | 0.86 | |||||
Grade 1 | 15 | 1 | 1 | ||||
Grade 2 | 68 | 1.84 | 0.23–14.71 | 0.58 | 0.32–1.04 | ||
Grade 3 | 39 | 2.10 | 0.25–17.96 | 0.40 | 0.21–0.79 | ||
Molecular subtype | 0.39 | 0.36 | |||||
Luminal | 78 | 1 | 1 | ||||
HER2-enriched | 32 | 1.73 | 0.71–4.24 | 0.87 | 0.23–3.22 | ||
Triple-negative | 33 | 1.65 | 0.67–4.03 | 1.90 | 0.71–5.11 | ||
IR signs a | |||||||
IR1 | 0.03 | 0.04 | |||||
IR1 = 0 | 109 | 1 | 1 | ||||
IR1 = 1 | 34 | 2.29 | 1.07–4.89 | 2.57 | 1.03–6.40 | ||
IR2 | 0.75 | 0.42 | |||||
IR2 = 0 | 61 | 1 | 1 | ||||
IR2 = 1 | 82 | 0.89 | 0.42–1.87 | 0.69 | 0.28–1.70 | ||
IR 3 | 0.33 | 0.53 | |||||
IR3 = 0 | 12 | 1 | 1 | ||||
IR3 = 1 | 131 | 2.71 | 0.37–19.95 | 1.91 | 0.26–14.34 | ||
IR 4 | 0.50 | 0.22 | |||||
IR4 = 0 | 114 | 1 | 1 | ||||
IR4 = 1 | 29 | 1.34 | 0.57–3.16 | 1.83 | 0.70–4.81 | ||
IR 5 | 0.47 | 0.93 | |||||
IR5 = 0 | 26 | 1 | 1 | ||||
IR5 = 1 | 117 | 1.48 | 0.51–4.27 | 0.95 | 0.32–2.87 |